The ability to detect and monitor potential toxicities of new clinical candidates is an absolute necessity for any pharmaceutical agent before the clinic. This safety profile is established during pre-clinical development through *in vitro* assays and animal studies. Although toxicities related to the mechanism of action may be readily detected, there is always a concern about the 'hidden toxicities\' that occur when a drug is combined with some other microenvironmental factor in animals or in the clinic. Wolenski *et al.*^[@bib1]^ described a model of synergistic cytotoxicity between the investigational agent pevonedistat (MLN4924) and the inflammatory cytokine TNF-*α*. The toxicity between pevonedistat and TNF-*α* was confirmed across multiple cultured cell lines, primary hepatocytes, and in rats. These non-clinical findings led to an improved understanding of the potential for clinical toxicities with pevonedistat that can occur in patients with a pre-existing inflammatory state.^[@bib2]^

Stimulation of the TNF-receptor (TNFR) results in a range of pro-survival outcomes (inflammation, innate immunity, etc.) that are all regulated by the NF-*κ*B transcription factor ([Figure 1a](#fig1){ref-type="fig"}).^[@bib3]^ However, excessive stimulation of the TNF signaling pathway can activate caspase-8, which in turn drives apoptosis.^[@bib4]^ In cell-based models, TNF-*α* and other pro-inflammatory cytokines were shown to synergize with pharmaceutical compounds to cause drug-induced injuries.^[@bib5]^ Similarly, *in vivo* models that couple perturbation of Toll-like receptor (TLR) signaling with selected small-molecule pharmaceuticals can trigger toxicity.^[@bib6]^

Pevonedistat is a small-molecule inhibitor of the NEDD8-activating enzyme (NAE) that has been evaluated in clinical trials for the treatment of cancer.^[@bib2]^ The role of NAE is to transfer NEDD8, an ubiquitin-like protein, to downstream substrates such as cullin-RING ligases (CRLs).^[@bib7]^ Proteins ubiquinated by the CRLs are targeted for proteasome-mediated degradation, and impaired turnover of the DNA replication factor CDT1 leads to cell cycle arrest ([Figure 1b](#fig1){ref-type="fig"}). In addition, pevonedistat indirectly inhibits NF-*κ*B signaling by preventing the degradation of I*κ*B*α*.^[@bib8]^ In a phase 1 trial, a subset of patients treated with high doses of pevonedistat experienced adverse events that included elevated hepatic transaminases following the first dose of pevonedistat.^[@bib2]^ The clinical findings served as the rationale to develop a pre-clinical model of pevonedistat drug-induced toxicity.

The manuscript by Wolenski *et al.*^[@bib1]^ identified that the combination of pevonedistat and TNF-*α* was cytotoxic both *in vitro* and *in vivo*. A hepatoma cell line became 50-fold more sensitive to TNF-*α* when dosed in combination with pevonedistat. Similarly, although rats tolerated the single agents alone, the combination resulted in liver damage. Additional cell-based characterizations found that pevonedistat and TNF-*α* specifically activated apoptosis, and inclusion of Z-VAD (a pan-caspase inhibitor) switched the mechanism of death to necroptosis ([Figure 1c](#fig1){ref-type="fig"}). Cells only tolerated pevonedistat and TNF-*α* when combined with Z-VAD (to block apoptosis) and Necrostatin-1 (to block necroptosis). Trimeric MLKL was also validated as a biomarker of active necroptosis, which is consistent with the literature.^[@bib9]^

A single protein, caspase-8, was the driver of pevonedistat and TNF-*α* cell death.^[@bib1]^ This was best illustrated through a knockdown of caspase-8 expression that prevented the pevonedistat and TNF-*α* synergistic cytotoxicity. Qualitatively, caspase-8 activity in the liver was also highest in rats that received the combination treatment. In cells, pevonedistat and TNF-*α* treatment preferentially resulted in the accumulation of the p10 protease subunit of caspase-8. This novel finding was interpreted as evidence for increased caspase processing/activation and not due to impaired protein degradation.

There remains a gap in the understanding of how pevonedistat sensitizes cells to cytotoxic TNF signaling (illustrated by a '?\' in [Figure 1c](#fig1){ref-type="fig"}). Specifically, one might determine which proteins in TNFR-to-caspase-8 pathway are affected by pevonedistat. Wolenski *et al.* investigated a known link between the CRL member cullin-3 and caspase-8 ubiquitination.^[@bib10],\ [@bib11]^ However, there was no evidence that caspase-8 was ubiquitinated in the pevonedistat model.^[@bib1]^ Knockdown of cullin-3 expression, which was hypothesized to make cells sensitive to TNF-*α* by mimicking pevonedistat, instead limited cell death caused by TNF-*α*. Thus, the exact mechanism of the toxicity requires additional work to fully characterize.

The clinical findings with pevonedistat necessitated an investigative effort to establish a pre-clinical model. Two key lessons were learned from this effort. First, a pre-clinical screening strategy should be employed to identify potential synergistic cytotoxicities between compounds and pro-inflammatory agents. Second, attention needs to given to determine whether regulated necrosis pathways, such as necroptosis, can contribute to drug-induced toxicities. There are multiple types of regulated necrosis, all of which cause the dysregulation of the redox metabolome.^[@bib12]^ Although pevonedistat only activated necroptosis in cultured cells under specific conditions, the results from Wolenski *et al.* suggest that compounds that affect the TNFR pathway may have similar effects.

From a broader perspective, the dysregulation of cell death is at the center of essentially every form of liver disease.^[@bib13]^ It is relevant to the understanding of liver toxicity to determine what activates these pathways, how these triggers and pathways influence liver toxicity, and to develop a cell-health assessment strategy for pre-clinical testing. This might be accomplished through a high-content imaging assessment such as proposed by Xu;^[@bib14]^ an *in vitro* screen such as described by Cosgrove;^[@bib5]^ and *in vivo* models such as those developed by Roth.^[@bib15]^ The objectives of all of these approaches is to identify and characterize the mechanisms that drive toxicity, and to define a set of comprehensive assays that improve early safety screening. Validation of these assays with existing compounds, such as pevonedistat, could lead to a better understanding of potential toxicities before compounds enter the clinic.
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![Pevonedistat synergizes with TNF-*α* to induce cell death. (**a**) Stimulation of the TNFR activates NF-*κ*B pro-survival signaling. NF-*κ*B is regulated by the degradation of its inhibitor I*κ*B*α* through the CRL-proteasome pathway. (**b**) Pevonedistat is an inhibitor of NEDD8-activating enzyme (NAE). Inhibition of NAE and thus the CRL-proteasome prevents the degradation of many proteins, such as CDT1 that in turn leads to DNA re-replication and cell cycle arrest. (**c**) The combination of pevonedistat and TNF-*α* kills cells through apoptosis. A pan-caspase inhibitor (Z-VAD) prevents apoptosis but cells then die by necroptosis through a RIP1-RIP3-MLKL mechanism. Combined with Z-VAD, the RIP1 inhibitor Necrostatin-1 (Nec-1) prevents cell death. Pevonedistat blocks NF-*κ*B signaling and has a putative effect on an unknown aspect of pathway that links the TNFR to caspase-8. Solid lines indicate a direct link, whereas dashed lines represent multiple intermediate steps](cddis2015321f1){#fig1}
